Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 1.00 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 1.00 |
| ▸ | CYP2A6 | P11509 | 6/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | FYN | P06241 | 1/20 | 0.55 |
| ▸ | KIF11 | P52732 | 1/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.52 |
| ▸ | VHL | P40337 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | WNT3A | P56704 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30462079 | 1.00 | MKNK1 (1.00) | MKNK1MKNK2CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL1138676 | 0.85 | MKNK1 (0.73) | MKNK1MKNK2CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL24534338 | 0.82 | CYP2A6 (0.88) | MKNK1MKNK2CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL13907273 | 0.82 | CYP2A6 (0.88) | MKNK1MKNK2CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL29360677 | 0.82 | CYP2A6 (0.88) | MKNK1MKNK2CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL16996659 | 0.82 | MKNK1 (0.70) | MKNK1MKNK2CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL30484231 | 0.81 | MKNK1 (0.68) | MKNK1MKNK2CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL4581739 | 0.81 | MKNK1 (0.68) | MKNK1MKNK2CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL844549 | 0.81 | MKNK1 (0.68) | MKNK1MKNK2CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL15531517 | 0.80 | CYP2A6 (0.67) | MKNK1MKNK2CYP2A6CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741386-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20250289799-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2025-09-18 | — | — | US | disclosed |
| US-20250161271-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING ANTICANCER AGENT AND NOVEL COMPOUND HAVING INHIBITORY ACTIVITY WITH RESPECT TO PROSTAGLANDIN E2 RECEPTORS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-05-22 | — | — | US | disclosed |
| EP-4516779-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2025-03-05 | — | — | EP | disclosed |
| WO-2025007777-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2025-01-09 | — | — | WO | disclosed |
| EP-4480477-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING ANTICANCER AGENT AND NOVEL COMPOUND HAVING INHIBITORY ACTIVITY WITH RESPECT TO PROSTAGLANDIN E2 RECEPTORS | Kanaph Therapeutics Inc. (KR) | 2024-12-25 | — | — | EP | disclosed |
| US-12016852-B2 | Pyrrolidine glycosidase inhibitors | ASCENEURON SA (CH) | 2024-06-25 | — | — | US | disclosed |
| US-12016852-B2 | Pyrrolidine glycosidase inhibitors | ASCENEURON SA (CH) | 2024-06-25 | — | — | US | disclosed |
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2023-11-16 | — | — | US | disclosed |
| EP-0986385-A4 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO INC (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-1011667-A4 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO INC (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-2001014358-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) DIHYDROBENZOFURANS AND BENOZOPYRANS | AVENTIS PHARMACEUTICALS INC. (DE) | 2001-03-01 | — | — | WO | disclosed |
| US-6156772-A | INDOLE HORMONE INHIBITORS | MERCK & CO., INC. (US) | 2000-12-05 | — | — | US | disclosed |
| WO-2000039087-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| EP-1011667-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | Merck & Co., Inc. (a New Jersey corp.) (US) | 2000-06-28 | — | — | EP | disclosed |
| EP-0986385-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO. INC. (US) | 2000-03-22 | — | — | EP | disclosed |
| US-5985901-A | TREATMENT OF A VARIETY OF SEX-HORMONE RELATED AND OTHER CONDITIONS IN BOTH MEN AND WOMEN | MERCK & CO., INC. (US) | 1999-11-16 | — | — | US | disclosed |
| WO-1998055119-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1998-12-10 | — | — | WO | disclosed |
| WO-1998055116-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1998-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12016852-B2 | Pyrrolidine glycosidase inhibitors | PREP, GAA, DNPEP | MKNK1 4094/4885MKNK2 4275/4885CYP2A6 2483/4885 |
| US-20250161271-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING ANTICANCER AGENT AND NOVEL COMPOUND HAVING INHIBITORY ACTIVITY WITH RESPECT TO PROSTAGLANDIN E2 RECEPTORS | PTGES2, PTGIR, PTGES | MKNK1 1639/4885MKNK2 1651/4885CYP2A6 314/4885 |
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | PTGER1, PTGIR, PTGDR2 | MKNK1 3446/4885MKNK2 2859/4885CYP2A6 457/4885 |
| US-20250289799-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | USP1, UPP1, UFL1 | MKNK1 2704/4885MKNK2 3010/4885CYP2A6 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.